ORKA
$41.41-0.34 (-0.81%)
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that t...
Recent News
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Oruka Therapeutics, Inc. (ORKA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Company News for Mar 16, 2026
Companies In The News Are: ADBE, META, NKTR, ORKA.
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Evaluating Oruka Therapeutics (ORKA) Valuation After Strong Recent Share Price Momentum
Oruka Therapeutics (ORKA) has drawn investor attention after a recent stretch where the share price showed mixed moves, including a small 1 day decline and a modest gain over the past 3 months. See our latest analysis for Oruka Therapeutics. Looking beyond the latest pullback, Oruka Therapeutics’ share price return over the past 90 days is 17.34%, while its year to date share price return is 13.94% and its 1 year total shareholder return is very large at 188.10%. This points to strong longer...
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA)
Oruka Therapeutics recently reported its third quarter 2025 results, including a net loss of US$30.28 million, and completed a major US$180 million PIPE financing to extend its cash runway beyond key upcoming clinical milestones. The company also presented promising early Phase 1 results for ORKA-001, suggesting potential for once-per-year dosing and sustained efficacy in treating psoriasis. We’ll explore how the combination of positive interim ORKA-001 data and strengthened financials may...